1. Home
  2. FRSH vs BEAM Comparison

FRSH vs BEAM Comparison

Compare FRSH & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Freshworks Inc.

FRSH

Freshworks Inc.

HOLD

Current Price

$9.96

Market Cap

2.9B

Sector

Technology

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$26.82

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRSH
BEAM
Founded
2010
2017
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
3.0B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
FRSH
BEAM
Price
$9.96
$26.82
Analyst Decision
Buy
Buy
Analyst Count
15
12
Target Price
$14.86
$50.75
AVG Volume (30 Days)
27.7M
2.7M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
296.88
82.31
EPS
N/A
N/A
Revenue
$838,809,000.00
$24,000.00
Revenue This Year
$16.30
N/A
Revenue Next Year
$14.09
$33.77
P/E Ratio
N/A
N/A
Revenue Growth
16.43
33.33
52 Week Low
$6.79
$15.60
52 Week High
$14.43
$38.26

Technical Indicators

Market Signals
Indicator
FRSH
BEAM
Relative Strength Index (RSI) 47.68 34.02
Support Level $9.75 $24.80
Resistance Level $10.69 $29.99
Average True Range (ATR) 0.51 2.20
MACD -0.04 -0.99
Stochastic Oscillator 17.29 5.39

Price Performance

Historical Comparison
FRSH
BEAM

About FRSH Freshworks Inc.

Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions. It derives maximum revenue from North America.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Share on Social Networks: